Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

308P - Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Nicolas Lindegger

Citation

Annals of Oncology (2020) 31 (suppl_4): S348-S395. 10.1016/annonc/annonc268

Authors

N. Lindegger1, C. Ike2, N.R.M. Schwartz2, A. Surinach3, Y. Liu4, A. Forero-Torres5, K. DeBusk2

Author affiliations

  • 1 Medical Affairs, Seattle Genetics - SeaGen International GmbH, 6300 - Zug/CH
  • 2 Health Economics And Outcomes Research, Seattle Genetics, 98021 - Bothell/US
  • 3 Real World Evidence Solutions, Genesis Research, 7030 - Hoboken/US
  • 4 Real World Evidence Solutions, Genesis Research, 07030 - Hoboken/US
  • 5 Medical Affairs, Seattle Genetics, 98021 - Bothell/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 308P

Background

The brain is a common site of metastasis among HER2-positive (HER2+) metastatic breast cancer (MBC) patients. However, data on the outcomes of patients with brain metastases (BM) versus other sites in the real-world are limited.

Methods

The full analysis included adult HER2+ MBC patients with and without BM identified in the Flatiron database from January 1, 2013 to May 31, 2019. To account for changes in systemic treatment options, e.g. introduction of trastuzumab emtansine (T-DM1), analysis was conducted in a subgroup of patients diagnosed after January 1, 2016. The study objectives were to explore outcomes and treatment patterns among patients with and without BM using electronic health records. Patient demographics, clinical characteristics, overall survival (OS), and treatment patterns were described. Adjusted cox proportional hazards models were used to compare OS across groups.

Results

The full analysis included 3,367 patients, and the subgroup included 1,755 patients. Patients with BM at MBC diagnosis (baseline BM) were younger than those without baseline BM (56.6 vs. 61.4 years). Among those without baseline BM, average time to BM diagnosis was 17.0 months. In both the full analysis and the subgroup, OS was shortest in patients with baseline BM (median OS 24.0 and 22.3 months, respectively), followed by patients without baseline BM who subsequently developed them (median OS 35.7 and 33.8 months). Patients without BM had the longest OS (median OS 41.1 months [40.2 months in the subgroup]). Patients with BM at any point had significantly shorter OS than patients without (HR 1.54, CI 1.28-1.85). Trastuzumab + pertuzumab-based therapy was the most common regimen in both 1L and 2L for patients with and without BM. Among BM patients, T-DM1 was the most common 3L regimen. Trastuzumab-based regimens were most common in 4L and 5L. Lapatinib regimens were used more frequently among BM patients, but were used in only 11-15%, depending on line of therapy.

Conclusions

BM remain a significant burden among patients with HER2+ MBC and are associated with significantly increased risk of mortality. Treatments that improve outcomes for HER2+ MBC patients who are at risk of developing BM over their disease course are needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Seattle Genetics.

Funding

Seattle Genetics.

Disclosure

N. Lindegger: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics; Shareholder/Stockholder/Stock options: Roche. C. Ike: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics. N.R.M. Schwartz: Full/Part-time employment, Paid student consultant: Seattle Genetics. A. Surinach: Research grant/Funding (institution), Paid consultant for this study: Seattle Genetics. Y. Liu: Research grant/Funding (institution), Paid consultant for this study: Seattle Genetics. A. Forero-Torres: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics. K. DeBusk: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics; Shareholder/Stockholder/Stock options: Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.